EM1709H "Targeted Therapy: What Does the Internist Really Need to Know?" (IM GR-092917)
The purpose of this presentation is to familiarize the audience with the typical toxicities and drug interactions associated with the commonly used molecularly targeted agents in oncology.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Recognize the common and serious side effects of the VEGF inhibitors
- Recognize the common and serious side effects of the EGFR inhibitors
- Understand the cardiac risk of HER-2 directed therapy
- Understand the cardiovascular risks of the ABL1 TKI’s
- Recognize potential autoimmune toxicities associated with the immune checkpoint inhibitors and basic management strategies for these toxicities
Jonathan E. Dowell, M.D.
Professor of Internal Medicine
Division of Hematology / Oncology
Chief, Section of Hematology / Oncology Veterans Affairs North Texas Healthcare System
- 1.00 AMA